TITLE:
Comprehensive Online Management Based on Cloud Platform for Breast Cancer Patients Using Dual-Targeted Therapy with Macromolecular Monoclonal Antibodies
AUTHORS:
Liping Zhang, Qiaoling Zhong, Lili Han, Lijuan Zhang, Qinghua Luo, Xinhua Xie, Zeyu Shuang, Na Li
KEYWORDS:
Breast Cancer, Dual-Targeted Therapy with Macromolecular Monoclonal An-tibodies, Cloud Platform, Comprehensive Online Management
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.13 No.9,
September
28,
2022
ABSTRACT: Objective: The purpose of the study was to explore the application effects of the
cloud platform-based comprehensive online management for breast cancer patients
using dual-targeted therapy with macromolecular monoclonal antibodies. Methods: 120 breast cancer patients treated by dual-targeted therapy with macromolecular
monoclonal antibodies were managed by a cloud platform from March to November
2019. Comprehensive online management included consultation about drugs and
side effects and frequently asked questions in the dual-targeted therapy with
macromolecular monoclonal antibodies. Results: In the consultation about
drugs and side effects, there were five patients with fever, neutrophil, cough,
and fatigue; 24 with diarrhea; 25 with nausea; 11 with oral mucosal
inflammation; 10 with rashes and dry skin; 8 with insomnia; and 1 with
palpitation. Moreover, 110 patients with anxiety about the missed or delayed
treatment were properly handled. Conclusion: The comprehensive online
management of dual-targeted therapy with macromolecular monoclonal antibodies
based on the cloud platform is helpful to satisfy the at-home breast cancer
patients’ needs, ensure the continuity of dual-targeted therapy with
macromolecular monoclonal antibodies for breast cancer patients, prevent
misinformation, alleviate patients’ negative psychological
emotions, and reduce patients’ economic losses. The online cloud
platform integrated management model is crucial for managing patients with
breast cancer treated by dual-targeted therapy.